10th Mediterranean Congress of Chemotherapy, Antalya, Turkey, 20 - 25 October 1996, pp.617-620
Changes in mitotic and labelling index were examined in present study, applying in vivo optimum doses of epirubicin, tamoxifen and epirubicin+tamoxifen to Ehrlich Ascites Tumour (EAT) cells. The findings reveal that treatments of epirubicin and tamoxifen lower the percentage of the cells at S phase and mitosis, while combined treatment of epirubicin and tamoxifen gives more successful results, being statistically significant (P<0.01).